Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

v3.22.2.2
Note 14 - Segments (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended September 30, 2022

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

Sales revenue:

                               

United States

  $     $     $     $  

International

    7,516                   7,516  

Grant and other revenue

                       

Total revenue

    7,516                   7,516  

Cost of revenue, excluding depreciation and amortization

    1,432                   1,432  

Reserve for expiring inventory

    133,006                   133,006  

Research and development expenses

    1,073,950       112,469             1,186,419  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          745       3,612,002       3,612,747  

Depreciation and amortization (2)

    8,532             16,171       24,703  

Income (loss) from operations (3)

    (1,209,404

)

    (113,214

)

    (3,628,173

)

    (4,950,791

)

Other expense, net (4)

                (757,034

)

    (757,034

)

Net loss

    (1,209,404

)

    (113,214

)

    (4,385,207

)

    (5,707,825

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 50,000     $     $ 5,929,692     $ 5,979,692  

International

    271,939             6,801       278,740  

Capital expenditures

    14,429                   14,429  

Three Months Ended September 30, 2021

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

License revenue

  $ 9,116     $     $     $ 9,116  

Grant and other revenue

    87,266                   87,266  

Total revenue

    96,382                   96,382  

Research and development expenses

    906,677       142,109             1,048,786  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          744       1,450,565       1,451,309  

Depreciation and amortization (2)

    6,040             12,026       18,066  

Loss from operations (3)

    (816,335

)

    (142,853

)

    (1,462,591

)

    (2,421,779

)

Other expense, net (4)

                (14

)

    (14

)

Income tax expense

    (5,763

)

    (824

)

    (9,457

)

    (16,043

)

Net loss

    (822,098

)

    (143,677

)

    (1,472,062

)

    (2,437,836

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 185,205     $     $ 8,557,398     $ 8,742,603  

International

    216,353             590       216,943  

Capital expenditures

                18,042       18,042  

Nine Months Ended September 30, 2022

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

Sales revenue:

                               

United States

  $     $     $     $  

International

    14,035                   14,035  

Grant and other revenue

    51,007                   51,007  

Total revenue

    65,042                   65,042  

Cost of revenue, excluding depreciation and amortization

    1,905                   1,905  

Reserve for expiring inventory

    133,006                   133,006  

Research and development expenses

    3,700,528       379,133             4,079,661  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          3,746       6,630,047       6,633,793  

Depreciation and amortization (2)

    20,613             48,739       69,352  

Loss from operations (3)

    (3,791,010

)

    (382,879

)

    (6,678,786

)

    (10,852,675

)

Other expense, net (4)

                (841,853

)

    (841,853

)

Net loss

    (3,791,010

)

    (382,879

)

    (7,520,639

)

    (11,694,528

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 50,000     $     $ 5,929,692     $ 5,979,692  

International

    271,939             6,801       278,740  

Capital expenditures

    54,650             8,436       63,086  

Nine Months Ended September 30, 2021

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

License revenue

  $ 44,665     $     $     $ 44,665  

Grant and other revenue

    436,500                   436,500  

Total revenue

    481,165                   481,165  

Research and development expenses

    3,359,190       410,406             3,769,596  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          3,623       5,073,435       5,077,058  

Depreciation and amortization (2)

    18,121             37,551       55,672  

Loss from operations (3)

    (2,896,146

)

    (414,029

)

    (5,110,986

)

    (8,421,161

)

Other income, net (4)

                358,436       358,436  

Income tax expense

    (5,763

)

    (824

)

    (9,457

)

    (16,043

)

Net loss

    (2,901,909

)

    (414,853

)

    (4,762,007

)

    (8,078,768

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 185,205     $     $ 8,557,398     $ 8,742,603  

International

    216,353             590       216,943  

Capital expenditures

                20,749       20,749